Illustrative photo
Market access, proven in the field.
10–15
Screened distributors per search
Detailed assessments and introductions for one MedTech or IVD product in one country.
$5,000
Starting scope, Country Intelligence
One product, one target country — a defensible market-entry decision. Request-first: no payment until scope is agreed in writing.
3
Flagship offers
Distributor Search · Country Intelligence · Clinical Adoption.
Products built for market access.
Three reviewed intelligence products for healthcare and MedTech manufacturers entering new countries.
Illustrative photo
A market-entry decision for your product — in your target country.
Start a Market Entry Project
Illustrative photo
Clinical Adoption Intelligence
Start a Market Entry ProjectView demonstration
How ghmap.io works
One chain. Proven at every step.
Most launches start with a distributor and a hope. ghmap.io starts where care happens — and only scales what clinicians have already tested and approved.
Illustrative photo
Doctor
Clinicians see the product first. Samples are placed with doctors and evaluated in real clinical practice.
Illustrative photo
Hospital
Hospitals test the product in their own setting. Their approval is the evidence everything else stands on.
Illustrative photo
Distributor
Only with demand proven do vetted distributors enter — matched to the market, the buyers, and the order flow.
Illustrative photo
Manufacturer
Manufacturers scale entry on field evidence, not assumptions — fewer failed launches, partnerships that last.
Brand film
Global access. Local impact.
A 66-second introduction to how ghmap.io structures market intelligence, regulatory context, professional relationships, and commercialization pathways — with English voiceover. The interface demo uses sample data, not customer records.
Professional review is required before business use. ghmap.io is not clinical decision support.
Start a Market Entry ProjectSee how field validation works.
Samples go to physicians and hospitals in the target country. They test, they report, they decide. ghmap.io turns their real-world feedback into the evidence behind your market-entry decision — before you commit your commercial budget.
The MELYVERA story: how a honey-based wound-care product was validated with physicians and hospitals on the ground — first order in Mali, September 2026.
See how it worksScope lock · Decision instrument
Then the evidence.
Reviewed intelligence for one healthcare or MedTech product in one target country.
Professional review is required before business use.
Country Intelligence delivered for
Wound-care market-entry work across Mali, Kenya and Nigeria.
“The GHMAP brief gave us a clear, evidence-based read on regulatory and distributor realities in West Africa before we committed our commercial budget. It is a critical tool for any MedTech team evaluating new markets.”
Where do you want to take your product?
Choose a product category, target country, and commercial objective. GHMAP uses this context to start the right request conversation.
Take the next step.
Start a request.
One product. One country. Reviewed intelligence — request-first, no payment until scope is agreed in writing.
Start a Market Entry ProjectPublic photographs and visualizations are illustrative unless identified as REAL platform registry data. GHMAP is not clinical decision support and does not provide diagnosis, treatment, legal, regulatory, reimbursement, or investment advice. Professional review and source verification are required before business use. See the disclaimer.